Fosbretabulin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Fosbretabulin
Accession Number
DB12577
Type
Small Molecule
Groups
Investigational
Description

Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
I5590ES2QZ
CAS number
222030-63-9
Weight
Average: 396.332
Monoisotopic: 396.097404634
Chemical Formula
C18H21O8P
InChI Key
WDOGQTQEKVLZIJ-WAYWQWQTSA-N
InChI
InChI=1S/C18H21O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H2,19,20,21)/b6-5-
IUPAC Name
{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxy}phosphonic acid
SMILES
COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1OP(O)(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Fosbretabulin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Fosbretabulin.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Fosbretabulin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fosbretabulin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Fosbretabulin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Fosbretabulin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Fosbretabulin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Fosbretabulin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Fosbretabulin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fosbretabulin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fosbretabulin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Fosbretabulin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Fosbretabulin.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Fosbretabulin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Fosbretabulin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Fosbretabulin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fosbretabulin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Fosbretabulin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Fosbretabulin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Fosbretabulin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5351387
PubChem Substance
347828799
ChemSpider
4508406
ChEMBL
CHEMBL1206232

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentEverolimus / Neuroendocrine Tumors1
1, 2RecruitingTreatmentCancer, Ovarian / Neoplasms, Ovarian1
2CompletedTreatmentCancers / Tumors1
2CompletedTreatmentMyopia, Degenerative / Subfoveal Choroidal Neovascularization1
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentPolypoidal Choroidal Vasculopathy (PCV)1
2CompletedTreatmentTumors1
2, 3TerminatedTreatmentAnaplastic Thyroid Cancers1
3WithdrawnTreatmentAnaplastic Thyroid Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00239 mg/mLALOGPS
logP2.41ALOGPS
logP2.72ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)1.62ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area103.68 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity100.22 m3·mol-1ChemAxon
Polarizability38.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Phenyl phosphates / Styrenes / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Organic oxides / Hydrocarbon derivatives
Substituents
Stilbene / Phenyl phosphate / Aryl phosphate / Aryl phosphomonoester / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Styrene / Alkyl aryl ether
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:58 / Updated on November 09, 2017 05:09